APA (7th ed.) Citation

Jr, F. R., A, N., J, F., MP, D., VH, L., MA, E., . . . N, R. (2025). Safety and immunogenicity of a Nipah virus vaccine (HeV-sG-V) in adults: A single-centre, randomised, observer-blind, placebo-controlled, phase 1 study. Lancet (London, England), 406(10521), 2792. https://doi.org/10.1016/S0140-6736(25)01390-X

Chicago Style (17th ed.) Citation

Jr, Frenck RW, et al. "Safety and Immunogenicity of a Nipah Virus Vaccine (HeV-sG-V) in Adults: A Single-centre, Randomised, Observer-blind, Placebo-controlled, Phase 1 Study." Lancet (London, England) 406, no. 10521 (2025): 2792. https://doi.org/10.1016/S0140-6736(25)01390-X.

MLA (9th ed.) Citation

Jr, Frenck RW, et al. "Safety and Immunogenicity of a Nipah Virus Vaccine (HeV-sG-V) in Adults: A Single-centre, Randomised, Observer-blind, Placebo-controlled, Phase 1 Study." Lancet (London, England), vol. 406, no. 10521, 2025, p. 2792, https://doi.org/10.1016/S0140-6736(25)01390-X.